Drugs / ARRY-502
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01349725 | May → Sep 2011 | — | Array BioPharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01561690 | Apr 2012 → May 2013 | asthma | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARRY-502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01561690 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL5314403 ↗1“CRTh2 antagonist” NCT01561690 ↗ |
| Modality | Small molecule | — CHEMBL5314403 ↗ |
| Route | Oral | “Oral; multiple dose, escalating” NCT01349725 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL5314403 ↗ |